Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387304 | 1.00 | IRAK4 (0.42) | IRAK4KDM4ECYP17A1AURKAFLT3 | |
| SCHEMBL18367192 | 0.79 | CYP17A1 (0.44) | IRAK4KDM4ECYP17A1AURKAFLT3 | |
| SCHEMBL30587545 | 0.79 | CYP17A1 (0.44) | IRAK4KDM4ECYP17A1AURKAFLT3 | |
| SCHEMBL343580 | 0.79 | KDM4E (0.56) | KDM4ERAB9ACYP1A2NPC1TP53 | |
| SCHEMBL24267834 | 0.78 | IRAK4 (0.40) | IRAK4KDM4ECYP17A1DPP4RAB9A | |
| SCHEMBL29390315 | 0.78 | IRAK4 (0.40) | IRAK4KDM4ECYP17A1DPP4RAB9A | |
| SCHEMBL5683198 | 0.77 | KDM4E (0.67) | IRAK4KDM4ECYP17A1AURKAFLT3 | |
| SCHEMBL29714856 | 0.77 | KDM4E (0.67) | IRAK4KDM4ECYP17A1AURKAFLT3 | |
| SCHEMBL24267830 | 0.77 | ALKBH2 (0.46) | IRAK4KDM4ECYP17A1DPP4RAB9A | |
| SCHEMBL29387563 | 0.77 | ALKBH2 (0.46) | IRAK4KDM4ECYP17A1DPP4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-01-04 | — | — | US | disclosed |
| CN-116249696-A | Pyrimidinone compounds and use thereof | 和记黄埔医药（上海）有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022037585-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-02-24 | — | — | WO | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | IRAK4 3365/4885KDM4E 3546/4885CYP17A1 59/4885 |
| US-20240002388-A1 | PYRIMIDINONE COMPOUNDS AND USES THEREOF | TYMP, DPYD, DHFR | IRAK4 2740/4885KDM4E 2745/4885CYP17A1 445/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | IRAK4 3365/4885KDM4E 3546/4885CYP17A1 59/4885 |
| US-12630554-B2 | Pyrimidinone compounds and uses thereof | CYP2D6, TPMT, CYP2B6 | IRAK4 3670/4885KDM4E 3657/4885CYP17A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.